Gain Therapeutics Inc.

NASDAQ: GANX · Real-Time Price · USD
2.06
-0.12 (-5.50%)
At close: May 02, 2025, 3:59 PM
2.03
-1.22%
After-hours: May 02, 2025, 05:24 PM EDT

Gain Therapeutics Statistics

Share Statistics

Gain Therapeutics has 28.75M shares outstanding. The number of shares has increased by 46.94% in one year.

Shares Outstanding 28.75M
Shares Change (YoY) 46.94%
Shares Change (QoQ) 0%
Owned by Institutions (%) 7.48%
Shares Floating n/a
Failed to Deliver (FTD) Shares 39
FTD / Avg. Volume 0.01%

Short Selling Information

The latest short interest is 279.72K, so 1.05% of the outstanding shares have been sold short.

Short Interest 279.72K
Short % of Shares Out 1.05%
Short % of Float 1.1%
Short Ratio (days to cover) 1

Valuation Ratios

The PE ratio is -2.42 and the forward PE ratio is -2.43. Gain Therapeutics's PEG ratio is 0.05.

PE Ratio -2.42
Forward PE -2.43
PS Ratio 0
Forward PS 2.7
PB Ratio 6.73
P/FCF Ratio -2.62
PEG Ratio 0.05
Financial Ratio History

Enterprise Valuation

Currently the Enterprise Value (EV) is not available for Gain Therapeutics.

EV / Sales n/a
EV / EBITDA n/a
EV / EBIT n/a
EV / FCF n/a

Financial Position

The company has a current ratio of 2.97, with a Debt / Equity ratio of 0.09.

Current Ratio 2.97
Quick Ratio 2.97
Debt / Equity 0.09
Debt / EBITDA -0.03
Debt / FCF -0.03
Interest Coverage 0

Financial Efficiency

Return on Equity is n/a and Return on Invested Capital is n/a.

Return on Equity n/a
Return on Assets n/a
Return on Invested Capital n/a
Revenue Per Employee n/a
Profits Per Employee $-887,443.09
Employee Count 23
Asset Turnover 0
Inventory Turnover n/a

Taxes

Income Tax 536.82K
Effective Tax Rate -2.7%

Stock Price Statistics

The stock price has increased by -30.41% in the last 52 weeks. The beta is 0.19, so Gain Therapeutics's price volatility has been higher than the market average.

Beta 0.19
52-Week Price Change -30.41%
50-Day Moving Average 1.96
200-Day Moving Average 1.85
Relative Strength Index (RSI) 56.47
Average Volume (20 Days) 278,988

Income Statement

Revenue n/a
Gross Profit n/a
Operating Income -20.35M
Net Income -20.41M
EBITDA -19.79M
EBIT n/a
Earnings Per Share (EPS) -0.89
Full Income Statement

Balance Sheet

The company has 10.39M in cash and 653.01K in debt, giving a net cash position of 9.73M.

Cash & Cash Equivalents 10.39M
Total Debt 653.01K
Net Cash 9.73M
Retained Earnings -81.19M
Total Assets 12.12M
Working Capital 7.69M
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -18.87M and capital expenditures -22.49K, giving a free cash flow of -18.9M.

Operating Cash Flow -18.87M
Capital Expenditures -22.49K
Free Cash Flow -18.9M
FCF Per Share -0.83
Full Cash Flow Statement

Margins

Gross Margin n/a
Operating Margin n/a
Pretax Margin n/a
Profit Margin n/a
EBITDA Margin n/a
EBIT Margin n/a
FCF Margin n/a

Dividends & Yields

GANX does not appear to pay any dividends at this time.

Dividend Per Share n/a
Dividend Yield n/a
Dividend Growth (YoY) n/a
Payout Ratio n/a
Earnings Yield n/a
FCF Yield n/a
Dividend Details

Analyst Forecast

The average price target for GANX is $7.5, which is 264.1% higher than the current price. The consensus rating is "Buy".

Price Target $7.5
Price Target Difference 264.1%
Analyst Consensus Buy
Analyst Count 5
Stock Forecasts

Scores

Altman Z-Score -7.27
Piotroski F-Score 2